OPRX Relative Valuation
OPRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OPRX is overvalued; if below, it's undervalued.
Historical Valuation
OptimizeRx Corp (OPRX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 20.28 is considered Undervalued compared with the five-year average of 60.73. The fair price of OptimizeRx Corp (OPRX) is between 14.91 to 58.04 according to relative valuation methord. Compared to the current price of 14.52 USD , OptimizeRx Corp is Undervalued By 2.59%.
Relative Value
Fair Zone
14.91-58.04
Current Price：14.52
2.59%
Undervalued
20.62
PE
1Y
3Y
5Y
Trailing
Forward
15.64
EV/EBITDA
OptimizeRx Corp. (OPRX) has a current EV/EBITDA of 15.64. The 5-year average EV/EBITDA is 55.14. The thresholds are as follows: Strongly Undervalued below -39.73, Undervalued between -39.73 and 7.71, Fairly Valued between 102.58 and 7.71, Overvalued between 102.58 and 150.02, and Strongly Overvalued above 150.02. The current Forward EV/EBITDA of 15.64 falls within the Historic Trend Line -Fairly Valued range.
56.42
EV/EBIT
OptimizeRx Corp. (OPRX) has a current EV/EBIT of 56.42. The 5-year average EV/EBIT is 133.63. The thresholds are as follows: Strongly Undervalued below -592.68, Undervalued between -592.68 and -229.53, Fairly Valued between 496.78 and -229.53, Overvalued between 496.78 and 859.93, and Strongly Overvalued above 859.93. The current Forward EV/EBIT of 56.42 falls within the Historic Trend Line -Fairly Valued range.
2.34
PS
OptimizeRx Corp. (OPRX) has a current PS of 2.34. The 5-year average PS is 6.03. The thresholds are as follows: Strongly Undervalued below -4.97, Undervalued between -4.97 and 0.53, Fairly Valued between 11.53 and 0.53, Overvalued between 11.53 and 17.03, and Strongly Overvalued above 17.03. The current Forward PS of 2.34 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
OptimizeRx Corp. (OPRX) has a current P/OCF of 0.00. The 5-year average P/OCF is 56.13. The thresholds are as follows: Strongly Undervalued below -164.69, Undervalued between -164.69 and -54.28, Fairly Valued between 166.55 and -54.28, Overvalued between 166.55 and 276.96, and Strongly Overvalued above 276.96. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
OptimizeRx Corp. (OPRX) has a current P/FCF of 0.00. The 5-year average P/FCF is 76.04. The thresholds are as follows: Strongly Undervalued below -159.65, Undervalued between -159.65 and -41.81, Fairly Valued between 193.88 and -41.81, Overvalued between 193.88 and 311.72, and Strongly Overvalued above 311.72. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
OptimizeRx Corp (OPRX) has a current Price-to-Book (P/B) ratio of 2.18. Compared to its 3-year average P/B ratio of 1.74 , the current P/B ratio is approximately 25.27% higher. Relative to its 5-year average P/B ratio of 3.97, the current P/B ratio is about -45.15% higher. OptimizeRx Corp (OPRX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 0.91%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 0.63% , the current FCF yield is about -100.00% lower.
2.21
P/B
Median3y
1.74
Median5y
3.97
4.41
FCF Yield
Median3y
0.91
Median5y
0.63
Competitors Valuation Multiple
The average P/S ratio for OPRX's competitors is 0.00, providing a benchmark for relative valuation. OptimizeRx Corp Corp (OPRX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 22.33%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of OPRX increased by 201.44% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 2.06K to 7.97K.
The secondary factor is the Revenue Growth, contributed 22.33%to the performance.
Overall, the performance of OPRX in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is OptimizeRx Corp (OPRX) currently overvalued or undervalued?
What is OptimizeRx Corp (OPRX) fair value?
How does OPRX's valuation metrics compare to the industry average?
What is the current P/B ratio for OptimizeRx Corp (OPRX) as of Dec 05 2025?
What is the current FCF Yield for OptimizeRx Corp (OPRX) as of Dec 05 2025?
What is the current Forward P/E ratio for OptimizeRx Corp (OPRX) as of Dec 05 2025?